Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7371 ER in Irritable Bowel Syndrome: randomized double-blind placebo-controlled crossover study
2004-000383-27Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of robalzotan in irritable bowel syndrome (IBS) (3 arms), sponsored by AstraZeneca. Primary endpoints: Rectal sensitivity change measured by Sensitivity Index (SI) and Rectal sensitivity and pain measured by Electronic Analogue Scale (EAS). Started Jun 2004; status: completed.
02
Drugs
robalzotan
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2004-000383-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000383-27.